[go: up one dir, main page]

MXPA04005420A - Composicion farmaceutica que comprende un agonista de receptor de 5ht1. - Google Patents

Composicion farmaceutica que comprende un agonista de receptor de 5ht1.

Info

Publication number
MXPA04005420A
MXPA04005420A MXPA04005420A MXPA04005420A MXPA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A
Authority
MX
Mexico
Prior art keywords
receptor agonist
pharmaceutical composition
composition
swallowed
dispersion
Prior art date
Application number
MXPA04005420A
Other languages
English (en)
Inventor
Julian Westrup
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA04005420A publication Critical patent/MXPA04005420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica para administracion oral capaz desintegrarse y dispersarse rapidamente dentro del tracto gastrointestinal que comprende un agonista de receptor de 5HT1 como ingrediente activo, en particular una composicion en forma de dosis solida que esta disenada para ser deglutida, y metodos de tratamiento de dolor cefalico, especialmente migrana, usando dicha composicion.
MXPA04005420A 2001-12-05 2002-12-04 Composicion farmaceutica que comprende un agonista de receptor de 5ht1. MXPA04005420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129117.8A GB0129117D0 (en) 2001-12-05 2001-12-05 Pharmaceutical composition
PCT/EP2002/013715 WO2003047552A2 (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Publications (1)

Publication Number Publication Date
MXPA04005420A true MXPA04005420A (es) 2004-10-11

Family

ID=9927051

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005420A MXPA04005420A (es) 2001-12-05 2002-12-04 Composicion farmaceutica que comprende un agonista de receptor de 5ht1.

Country Status (28)

Country Link
US (1) US20050032867A1 (es)
EP (2) EP1450770B1 (es)
JP (1) JP3699969B2 (es)
KR (1) KR100591237B1 (es)
CN (1) CN1289069C (es)
AR (1) AR037627A1 (es)
AT (1) ATE291900T1 (es)
AU (1) AU2002358602B2 (es)
BR (1) BR0214497A (es)
CA (1) CA2469019C (es)
CO (1) CO5580741A2 (es)
DE (1) DE60203537T2 (es)
ES (1) ES2236608T3 (es)
FI (1) FI20022128A7 (es)
GB (1) GB0129117D0 (es)
HU (1) HU229313B1 (es)
IL (1) IL161997A (es)
IS (1) IS2481B (es)
MX (1) MXPA04005420A (es)
MY (1) MY129314A (es)
NO (1) NO329896B1 (es)
NZ (1) NZ532829A (es)
PL (1) PL194702B1 (es)
PT (1) PT1450770E (es)
RU (1) RU2285526C2 (es)
TW (1) TWI240638B (es)
WO (1) WO2003047552A2 (es)
ZA (1) ZA200403849B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP2006522790A (ja) * 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
AU2004247076A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and NSAIDs
CA2566384C (en) * 2004-05-28 2010-08-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP3449928A1 (en) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
WO2007130373A2 (en) * 2006-05-01 2007-11-15 Capricorn Pharma, Inc. Novel triptan formulations and methods for making them
US20080081072A1 (en) * 2006-09-30 2008-04-03 Cherukuri S R Resin-complex granulation for water-soluble drugs and associated methods
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
BR112022021089A2 (pt) * 2020-04-24 2022-12-06 Astrazeneca Ab Formulações farmacêuticas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9027827D0 (en) * 1990-12-21 1991-02-13 Glaxo Laboratoires Pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
WO1999043306A1 (en) * 1998-02-26 1999-09-02 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
AU2023401A (en) * 1999-12-01 2001-06-12 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine

Also Published As

Publication number Publication date
JP2005515991A (ja) 2005-06-02
US20050032867A1 (en) 2005-02-10
NO20025805D0 (no) 2002-12-03
KR100591237B1 (ko) 2006-06-19
AU2002358602B2 (en) 2005-05-26
KR20050044720A (ko) 2005-05-12
FI20022128A0 (fi) 2002-12-03
RU2285526C2 (ru) 2006-10-20
CO5580741A2 (es) 2005-11-30
ES2236608T3 (es) 2005-07-16
EP1450770A2 (en) 2004-09-01
IL161997A0 (en) 2005-11-20
EP1450770B1 (en) 2005-03-30
ZA200403849B (en) 2005-10-26
PL370669A1 (en) 2005-05-30
CA2469019A1 (en) 2003-06-12
PL194702B1 (pl) 2007-06-29
NZ532829A (en) 2005-05-27
AR037627A1 (es) 2004-11-17
IS7293A (is) 2004-06-03
WO2003047552A2 (en) 2003-06-12
DE60203537D1 (de) 2005-05-04
BR0214497A (pt) 2004-10-19
TWI240638B (en) 2005-10-01
RU2004120292A (ru) 2005-04-10
FI20022128L (fi) 2003-06-06
HUP0402178A2 (hu) 2005-02-28
DE60203537T2 (de) 2005-09-15
HUP0402178A3 (en) 2011-05-30
GB0129117D0 (en) 2002-01-23
CA2469019C (en) 2005-09-13
HK1069111A1 (en) 2005-05-13
PT1450770E (pt) 2005-08-31
MY129314A (en) 2007-03-30
CN1289069C (zh) 2006-12-13
JP3699969B2 (ja) 2005-09-28
FI20022128A7 (fi) 2003-06-06
IS2481B (is) 2008-12-15
TW200304384A (en) 2003-10-01
HU229313B1 (en) 2013-10-28
NO20025805L (no) 2003-06-06
NO329896B1 (no) 2011-01-24
ATE291900T1 (de) 2005-04-15
IL161997A (en) 2005-12-18
AU2002358602A1 (en) 2003-06-17
WO2003047552A3 (en) 2003-09-25
CN1610539A (zh) 2005-04-27
EP1527773A1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
PL367277A1 (en) Methods of making sustained release formulations of oxymorphone related applications
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
TW200633730A (en) Oral disintegrating dosage forms
EP2248519A3 (en) Non-mucoadhesive film dosage forms
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
IL165279A (en) Use of alpha-adrenergic agonists and alpha-2a antagonists for the preparation of pharmaceutical compositions for alleviating pain
RS56252B1 (sr) Jednodnevne formulacije oksikodona
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
MX2007005238A (es) Una composicion veterinaria transmucosal que comprende detomidina.
NZ594669A (en) Oral composition of Vorinostat
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
AU2001246388A1 (en) Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
TW200505504A (en) Saquinavir mesylate oral dosage form

Legal Events

Date Code Title Description
FG Grant or registration